Hormonal
Gamma-linolenic acid (GLA) improves the efficacy and reduces the side effects of tamoxifen in breast cancer patients, including improving transcutaneous absorption.
If you are taking tamoxifen for breast cancer, ask your oncologist about adding GLA. Research suggests it may help the drug work better, reduce side effects, and potentially speed up how quickly you respond to therapy. It may also help deliver the drug more effectively through the skin if using topical forms.
Clinical trial in breast cancer patients has confirmed that when given in combination with tamoxifen, GLA improved the efficacy of tamoxifen, reduced the side effects and time to response to therapy [20].
Why this rating
Based on a review of clinical trials and in-vitro studies, but specific large-scale trial data is not detailed in this text.
Source
Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Rakesh Kapoor et al. · Current Pharmaceutical Biotechnology · 2006
DOI 10.2174/138920106779116874
More from this paper
- Gamma-linolenic acid (GLA) supplementation reduces inflammation and joint symptoms in rheumatoid arthritis patients, acting as an NSAID-sparing agent by producing anti-inflammatory prostaglandins (PGE1) and leukotrienes (LTB4 inhibition).Moderate
- Gamma-linolenic acid (GLA) improves nerve conduction velocity in diabetic patients, leading to improved blood flow and reduced tingling in extremities.Moderate
- Gamma-linolenic acid (GLA) exhibits tumoricidal activity against various cancers (breast, pancreas, colon, brain) and inhibits metastasis by downregulating osteonectin and stimulating metastasis suppressor genes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →